Advanced search
Publication Cover
Cancer Investigation Volume 20, 2002 - Issue 1
Submit an article Journal homepage
74
Views
22
CrossRef citations to date
0
Altmetric
Original

Randomized Phase II Study of Irinotecan Plus Mitomycin C vs. Oxaliplatin Plus Mitomycin C in Patients with Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer

Werner Scheithauer Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Waehringer Guertel 18-20, Vienna, A-1090, Austria
, M.D.,
Gabriela V. Kornek Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Waehringer Guertel 18-20, Vienna, A-1090, Austria
, M.D.,
Stefan Brugger Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Waehringer Guertel 18-20, Vienna, A-1090, Austria
, M.D.,
Herbert Ullrich-Pur Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Waehringer Guertel 18-20, Vienna, A-1090, Austria
, M.D.,
Julia Valencak Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Waehringer Guertel 18-20, Vienna, A-1090, Austria
, M.D.,
Markus Raderer Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Waehringer Guertel 18-20, Vienna, A-1090, Austria
, M.D.,
Wolfgang Fiebiger Department of Internal Medicine I, Division of Oncology, Vienna University Medical School, Waehringer Guertel 18-20, Vienna, A-1090, Austria
, M.D.,
Erwin Kovats Department of Surgery, General Hospital of Baden, Austria
, M.D.,
Fritz Lang Department of Surgery, General Hospital of Neunkirchen, Austria
, M.D. &
Dieter Depisch Department of Surgery, General Hospital of Wr.Neustadt, Austria
, M.D show all
Pages 60-68 | Published online: 22 Apr 2002

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Muhammad Wasif Saif. (2020) Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity. OncoTargets and Therapy 13, pages 10197-10206.
Read now
Anastasios Dimou, Kostas N Syrigos & Muhammad Wasif Saif. (2010) Is there a role for mitomycin C in metastatic colorectal cancer?. Expert Opinion on Investigational Drugs 19:6, pages 723-735.
Read now
Shousong Cao, Arup Bhattacharya, Farukh A Durrani & Marwan Fakih. (2006) Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Expert Opinion on Pharmacotherapy 7:6, pages 687-703.
Read now
Michele Reni, M. G. Panucci, P. Passoni, E. Bonetto, R. Nicoletti, M. Ronzoni, A. Zerbi, C. Staudacher, V. Di Carlo & E. Villa. (2004) Salvage Chemotherapy with Mitomycin, Docetaxel, and Irinotecan (MDI Regimen) in Metastatic Pancreatic Adenocarcinoma: A Phase I and II Trial. Cancer Investigation 22:5, pages 688-696.
Read now

Articles from other publishers (18)

Simone Mocellin, Zora Baretta, Marta Roqué i Figuls, Ivan Solà, Marta Martin-Richard, Sara Hallum & Xavier Bonfill Cosp. (2017) Second-line systemic therapy for metastatic colorectal cancer. Cochrane Database of Systematic Reviews.
Crossref
Jo?o Paulo da Silveira Nogueira Lima, Fabiano Hahn de Souza, Dioc?sio Alves Pinto de Andrade, Jos? Barreto Campello Carvalheira & Lucas Vieira dos Santos. (2012) Independent Radiologic Review in Metastatic Colorectal Cancer: Systematic Review and Meta-Analysis. Radiology 263:1, pages 86-95.
Crossref
Renata Ferrarotto, Karime Machado, Milena P. Mak, Neeraj Shah, Tiago K. Takahashi, Frederico P. Costa, Michael J. Overman, Scott Kopetz & Paulo M. Hoff. (2012) A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. European Journal of Cancer 48:6, pages 820-826.
Crossref
S. Wu, X. Lu, Z. L. Zhang, P. Lei, P. Hu, M. Wang, B. Huang, W. Xing, X. T. Jiang, H. J. Liu, Z. G. Zhu, W. H. Li, H. F. Zhu, N. Fu & G. X. Shen. (2010) CC chemokine ligand 21 enhances the immunogenicity of the breast cancer cell line MCF-7 upon assistance of TLR2. Carcinogenesis 32:3, pages 296-304.
Crossref
Linda J.M. Oostendorp, Peep F. Stalmeier, Pieternel C. Pasker-de Jong, Winette T. Van der Graaf & Petronella B. Ottevanger. (2010) Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anti-Cancer Drugs 21:8, pages 749-758.
Crossref
Edward James, Maeve G. Waldron-Lynch & Muhammad Wasif Saif. (2009) Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anti-Cancer Drugs 20:7, pages 634-638.
Crossref
Emmanuel Mitry, Astrid Lièvre, Jean-Baptiste Bachet & Philippe Rougier. (2009) Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. International Journal of Colorectal Disease 24:6, pages 605-612.
Crossref
E. Mrozek, J. Kolesar, D. Young, J. Allen, M. Villalona-Calero & C.L. Shapiro. (2008) Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Annals of Oncology 19:8, pages 1417-1422.
Crossref
Vassilis Golfinopoulos, Georgia Salanti, Nicholas Pavlidis & John PA Ioannidis. (2007) Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. The Lancet Oncology 8:10, pages 898-911.
Crossref
Laurenz Vormittag, Gabriela V. Kornek, Barbara Gruhsmann, Alfred Lenauer, Andreas Föger, Dieter Depisch, Fritz Lang & Werner Scheithauer. (2007) UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer – a retrospective analysis. Anti-Cancer Drugs 18:6, pages 709-712.
Crossref
Salah-Eddin Al-Batran, Anne Kerber, Akin Atmaca, Claudius Dechow, Ernst Reitsamer, Sebastian Schmidt, Yvonne Kolassa, Antje Neumann, Eckhart Weidmann, Joerg Thomas Hartmann & Elke Jäger. (2007) Mitomycin C, 5-Fluorouracil, Leucovorin, and Oxaliplatin as a Salvage Therapy for Patients with Cisplatin-Resistant Advanced Gastric Cancer: A Phase I Dose Escalation Trial. Oncology Research and Treatment 30:1-2, pages 29-34.
Crossref
Christoph M. Ahlers, Kevin Camphausen, Deborah Citrin, Philip M. Arlen & James L. Gulley. (2006) A Pilot Trial of a Carcinoembryonic Antigen/TRICOM—Based Vaccine and Radiation to Liver Metastases in Patients with Carcinoembryonic Antigen—Positive Solid Tumors. Clinical Colorectal Cancer 6:1, pages 72-75.
Crossref
D. Lawes & I. Taylor. (2005) Chemotherapy for colorectal cancer—an overview of current management for surgeons. European Journal of Surgical Oncology (EJSO) 31:9, pages 932-941.
Crossref
Myung-Ah LeeJae-Ho ByunByoung-Young ShimIn-Sook WooJin-Hyung KangYoung Seon HongKyung Shik LeeMyung Gyu ChoiSuk Kyun ChangSeong Taek OhSung Il ChoiDoo Suk Lee. (2005) Irinotecan, Continuous 5-Fluorouracil, and Low dose of Leucovorin (modified FOLFIRI) as First Line of Therapy in Recurrent or Metastatic Colorectal Cancer. The Korean Journal of Internal Medicine 20:3, pages 205.
Crossref
J T Hartmann, K Oechsle, D Quietzsch, A Wein, R D Hofheinz, F Honecker, O Nehls, C-H Köhne, G Käfer, L Kanz & C Bokemeyer. (2003) Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. British Journal of Cancer 89:11, pages 2051-2056.
Crossref
J. Cassidy & H. Hochster. (2003) New oxaliplatin-based combinations in the treatment of colorectal cancer. Colorectal Disease 5, pages 1-9.
Crossref
Javier Sastre, Rosario Alfonso, Jos? Antonio Mac?as, Isabel Manrique, Luis Flores & Eduardo D?az-Rubio. (2003) 5-Fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line. Anti-Cancer Drugs 14:7, pages 543-547.
Crossref
Otto Soepenberg, Alex Sparreboom & Jaap Verweij. 2003. 1 50 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.